St Louis Trust’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

St Louis Trust’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-163,488	Closed	-$21.6M	–	126
2025 Q1	$21.6M	Buy	+163,488	New	+$20.4M	3.12%	10
2023 Q4	–	Sell	-5,000	Closed	-$260K	–	108
2023 Q3	$260K	Hold	5,000	–	–	0.05%	99
2023 Q2	$317K	Hold	5,000	–	–	0.06%	91
2023 Q1	$271K	Hold	5,000	–	–	0.05%	94
2022 Q4	$265K	Buy	+5,000	New	+$251K	0.06%	91
2022 Q3	–	Sell	-5,000	Closed	-$285K	–	105
2022 Q2	$285K	Hold	5,000	–	–	0.06%	89
2022 Q1	$306K	Sell	5,000 -7,870	-61%	-$409K	0.07%	89
2021 Q4	$674K	Buy	+12,870	New	+$541K	0.14%	81
2021 Q3	–	Sell	-5,000	Closed	-$204K	–	112
2021 Q2	$204K	Buy	+5,000	New	+$185K	0.05%	94
2020 Q3	–	Sell	-881,056	Closed	-$22.6M	–	88
2020 Q2	$22.6M	Hold	881,056	–	–	6.77%	5
2020 Q1	$13.5M	Buy	+881,056	New	+$19.1M	5.12%	5

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

St Louis Trust's ITCI Position: Q2 2025 in Review

St Louis Trust sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 163,488 shares — an estimated $21.6M sold.

St Louis Trust first reported a position in ITCI in Q1 2020 and held it in 11 quarters. The position peaked at $22.6M in Q2 2020. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

St Louis Trust reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
St Louis Trust sold 163,488 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $21.6M.
St Louis Trust first reported a position in Intra-Cellular Therapies Inc. in Q1 2020 and held it in 11 quarters.
St Louis Trust's Intra-Cellular Therapies Inc. position peaked at $22.6M in Q2 2020.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on St Louis Trust's 13F filing for Q2 2025, filed 25 Jul 2025.